Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Open, Blinded Endpoint (PROBE) Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

NCT05542576 is registered in ClinicalTrials.gov with Amydis Inc. as lead sponsor.

NCT NCT05542576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05542576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Open, Blinded Endpoint (PROBE) Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
Lead sponsor
Amydis Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 24, 2022
Completion date
March 15, 2023
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis, parkinson disease